Humana · Injectafer · US health-plan appeal rights

Injectafer denied as not FDA-approved for this use by Humana?

Q: How long do I have to appeal a Humana Injectafer denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana IV Iron in IBD — Active Crohn's / UC

The Humana angle on Injectafer

## Why Humana Denied Injectafer as Not FDA-Approved

A "not FDA-approved" denial for Injectafer (ferric carboxymaltose) typically means Humana has determined that the specific indication documented in the authorization request is not listed in the FDA-approved prescribing label — in other words, the use is off-label. This denial does not mean the drug itself lacks FDA approval; Injectafer holds FDA approval for defined indications. The question at appeal is whether your prescriber's stated indication is within that approved labeling, or if off-label, whether it is supported by authoritative clinical evidence.

This denial is worth examining closely and appealing. If the use is actually on-label, the denial rests on a factual error that can be corrected with the label itself. If the use is genuinely off-label, federal and state laws, as well as many plan documents, provide coverage pathways for off-label uses supported by recognized medical compendia or major guideline organizations.

## Federal Appeal Framework

ACA §2719 entitles non-grandfathered plan members to an internal appeal followed by independent external review. ERISA §503 provides full-and-fair review rights for employer plans. The external-review window is typically four months from the denial. Expedited review is available for urgent situations, with a 72-hour turnaround requirement.

## Concrete Appeal Steps

1. Confirm with your prescriber whether the documented indication is on-label or off-label relative to the current FDA-approved Injectafer prescribing label. 2. If on-label: submit the relevant label section with the appeal — the denial should be reversed. 3. If off-label: identify which major clinical guideline organization (e.g., ASH, ADA, ACC, or the relevant specialty society) includes this use in published guidance. 4. Check your plan's drug coverage policy for off-label use provisions — many plans cover uses listed in recognized compendia. 5. File the internal appeal with the label and/or guideline reference, then proceed to external review if denied.

## Documentation to Gather

FDA-approved prescribing label: The current Injectafer label, with the applicable indication highlighted.
Prescriber letter: Specifies the exact indication being treated, cites the label or applicable guideline organization, and explains the clinical reasoning.
Diagnosis confirmation: Chart documentation establishing the diagnosis corresponding to the claimed indication.
Prior-treatment history: Treatments tried before Injectafer, with dates and outcomes.

## Criteria-Mapping Structure

Build a response table using the Injectafer FDA label and Humana's published off-label or drug coverage policy:

| Humana denial basis | Rebuttal evidence | |---|---| | Indication not in FDA label | [Cite label section, or identify as off-label] | | Off-label use not covered under plan | [Cite plan's off-label coverage provision + guideline organization] | | Clinical necessity for this indication | [Prescriber letter + chart documentation] |

An IRO conducting external review evaluates the same label and guideline evidence and is not bound by Humana's interpretation. A factual rebuttal citing the label directly is among the most straightforward appeals to win.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other insurers on Injectafer

Other denial reasons for Humana Injectafer

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.